News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,151 Results
Type
Article (44227)
Company Profile (308)
Press Release (681616)
Multimedia
Podcasts (93)
Webinars (12)
Section
Business (212355)
Career Advice (2184)
Deals (37097)
Drug Delivery (115)
Drug Development (84227)
Employer Resources (177)
FDA (16724)
Job Trends (15584)
News (359972)
Policy (34447)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (5)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2632)
Accelerated approval (5)
Adcomms (26)
Allergies (90)
Alliances (52073)
ALS (94)
Alzheimer's disease (1411)
Antibody-drug conjugate (ADC) (143)
Approvals (16714)
Artificial intelligence (274)
Autoimmune disease (26)
Automation (16)
Bankruptcy (377)
Best Places to Work (11842)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (193)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (285)
Cancer (2331)
Cardiovascular disease (191)
Career advice (1819)
Career pathing (33)
CAR-T (158)
Cell therapy (438)
Cervical cancer (19)
Clinical research (68459)
Collaboration (878)
Compensation (539)
Complete response letters (28)
COVID-19 (2685)
CRISPR (45)
C-suite (251)
Cystic fibrosis (103)
Data (2224)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (284)
Diagnostics (6484)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (125)
Drug pricing (120)
Drug shortages (31)
Duchenne muscular dystrophy (96)
Earnings (88719)
Editorial (40)
Employer branding (21)
Employer resources (152)
Events (116452)
Executive appointments (742)
FDA (17996)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (769)
Gene editing (113)
Generative AI (24)
Gene therapy (323)
GLP-1 (795)
Government (4613)
Grass and pollen (5)
Guidances (59)
Healthcare (19148)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (134)
Indications (30)
Infectious disease (2838)
Inflammatory bowel disease (142)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (340)
IPO (16949)
IRA (48)
Job creations (4163)
Job search strategy (1555)
Kidney cancer (11)
Labor market (38)
Layoffs (507)
Leadership (22)
Legal (8531)
Liver cancer (76)
Lung cancer (331)
Lymphoma (156)
Machine learning (7)
Management (61)
Manufacturing (328)
MASH (71)
Medical device (13510)
Medtech (13515)
Mergers & acquisitions (20695)
Metabolic disorders (751)
Multiple sclerosis (85)
NASH (20)
Neurodegenerative disease (100)
Neuropsychiatric disorders (33)
Neuroscience (1982)
NextGen: Class of 2025 (6726)
Non-profit (4556)
Northern California (2682)
Now hiring (39)
Obesity (408)
Opinion (249)
Ovarian cancer (77)
Pain (96)
Pancreatic cancer (84)
Parkinson's disease (156)
Partnered (21)
Patents (242)
Patient recruitment (110)
Peanut (50)
People (59803)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21334)
Phase II (30075)
Phase III (22528)
Pipeline (1214)
Policy (160)
Postmarket research (2685)
Preclinical (9022)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (255)
Rare diseases (408)
Real estate (6367)
Recruiting (67)
Regulatory (23489)
Reports (46)
Research institute (2393)
Resumes & cover letters (370)
Rett syndrome (5)
RNA editing (5)
RSV (48)
Schizophrenia (77)
Series A (133)
Series B (87)
Service/supplier (14)
Sickle cell disease (55)
Southern California (2301)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3793)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (43)
The Weekly (62)
United States (23349)
Vaccines (722)
Venture capitalists (41)
Weight loss (288)
Women's health (36)
Worklife (16)
Date
Today (110)
Last 7 days (866)
Last 30 days (2668)
Last 365 days (33716)
2025 (10842)
2024 (36148)
2023 (40930)
2022 (52113)
2021 (56674)
2020 (55108)
2019 (47821)
2018 (36140)
2017 (33571)
2016 (33169)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (809)
Alabama (53)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (41709)
Australia (6626)
California (6139)
Canada (2024)
China (547)
Colorado (269)
Connecticut (274)
Delaware (151)
Europe (89459)
Florida (922)
Georgia (204)
Idaho (57)
Illinois (547)
India (26)
Indiana (321)
Iowa (11)
Japan (165)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (907)
Massachusetts (4623)
Michigan (219)
Minnesota (392)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (63)
New Jersey (1746)
New Mexico (31)
New York (1743)
North Carolina (1016)
North Dakota (8)
Northern California (2682)
Ohio (205)
Oklahoma (14)
Oregon (40)
Pennsylvania (1384)
Puerto Rico (13)
Rhode Island (33)
South America (1184)
South Carolina (22)
South Dakota (1)
Southern California (2301)
Tennessee (102)
Texas (915)
Utah (184)
Virginia (153)
Washington D.C. (62)
Washington State (560)
West Virginia (3)
Wisconsin (56)
726,151 Results for "hookipa pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. today announced that members of HOOKIPA’s Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET.
May 30, 2024
·
5 min read
Pharm Country
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma Inc. announced that members of HOOKIPA’s Executive Team will host an investor call summarizing the Company’s constructive regulatory interactions with the U.S. Food & Drug Administration and the European Medicines Agency.
April 10, 2024
·
5 min read
Pharm Country
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
HOOKIPA Pharma Inc. announced that HOOKIPA’s Chief Financial Officer, Reinhard Kandera, will present at the Leerink Partners Global Biopharma Conference on March 13, 2024.
March 6, 2024
·
3 min read
Press Releases
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
January 30, 2025
·
6 min read
Business
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported financial results and recent business highlights for the first quarter of 2024.
May 9, 2024
·
11 min read
Press Releases
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
November 12, 2024
·
6 min read
Pharm Country
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive head and neck cancers.
May 23, 2024
·
11 min read
Drug Development
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma Inc. today announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer.
June 4, 2024
·
10 min read
Pharm Country
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
HOOKIPA Pharma Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-statutory options to Mark Winderlich, who was appointed Chief Development Officer of the Company effective April 1, 2024, to purchase an aggregate of 250,000 shares of the Company’s Common Stock under HOOKIPA’s 2023 Inducement Plan.
April 16, 2024
·
2 min read
Business
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the fourth quarter and full year 2023.
March 22, 2024
·
15 min read
1 of 72,616
Next
